May 13, 2022 7:00am EDT ProMIS Holds Annual and Special Meeting of Shareholders All Resolutions Approved
May 03, 2022 7:00am EDT Independent Proxy Advisory Firms, ISS and Glass Lewis, Recommend ProMIS Shareholders Vote FOR All Proposed Items at the Upcoming Annual and Special Meeting of Shareholders
Apr 28, 2022 7:00am EDT ProMIS Neurosciences Reports New Milestones in Potential Therapeutic Approaches for Amyotrophic Lateral Sclerosis (ALS)
Apr 19, 2022 7:00am EDT ProMIS appoints experienced industry veteran Larry Altstiel as Chief Medical Officer
Apr 07, 2022 7:00am EDT ProMIS Neurosciences Presents at the 2022 American Academy of Neurology Annual Meeting
Apr 07, 2022 7:00am EDT ProMIS Files Management Information Circular in Connection with Annual General and Special Meeting of Shareholders
Mar 24, 2022 7:00am EDT ProMIS Neurosciences to Present at the 10th Annual Neurodegenerative Drug Development Summit
Mar 22, 2022 7:00am EDT ProMIS Neurosciences Presents Preclinical Results of its Experimental Alzheimer’s Vaccine at the 2022 International AD/PDTM Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders